Stockreport

IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study

Imunon, Inc.  (IMNN) 
PDF IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer  Patient enrollment in Phase 3 pivotal trial of IMN [Read more]